SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

NCT02967679 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy
Peripheral Neuropathy
Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease Type 1A
Charcot-Marie-Tooth Disease, Type 1B
Anti-MAG Neuropathy

Interventions

DRUG: MD1003

Sponsor

MedDay Pharmaceuticals SA